logo image
search icon
Global Rare Kidney Diseases Market

Rare Kidney Diseases Market Size, Share & Trends Analysis Report By Target Indication, By Type of Molecule (Small Molecules, Biologics, By Route of administration (Oral, Intravenous, Subcutaneous, Others), By End-User, By Distribution, By Region, And By Segment Forecasts, 2023-2031.

Report ID : 1414 | Published : 2023-04-18 | Pages: 190 | Format: PDF/EXCEL

The Rare Kidney Diseases Market Size is valued at 2528.9 Million in 2022 and is predicted to reach 5738.7 Million by the year 2031 at a 9.7% CAGR during the forecast period for 2023-2031.

Rare Kidney Diseases Market

Kidney diseases have the potential to intensify over time, eventually leading to kidney failure, which is when the kidneys completely stop working. In addition, having one of these diseases can put you at a higher risk for developing another condition, such as cardiovascular disease. At least 150 distinct conditions are classified as rare kidney diseases, and the majority are inherited. The diagnosis and treatment of rare kidney diseases as a group may present overlapping difficulties, even though individual cases of these diseases present unique obstacles. Diagnosis, management, and treatment of inherited kidney disorders are complicated, especially when multisystem complications are present. These diseases can result in numerous physical and mental impairments, lowering life expectancy and reducing the quality of life. In the last two years, the COVID-19 infection severely affected the human lifestyle and approach towards chronic disease treatment. This led to delayed detection of rare kidney diseases and became responsible for the increase in the number of patients.

Several important factors are responsible for the growth of the rare kidney disease market. It is anticipated that the increasing use of next-generation sequencing techniques will improve diagnostic accuracy for rare kidney diseases, aid in elucidating the molecular mechanism of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility allow for more prolonged patient survival, but frequently at the expense of their quality of life. FDA approvals, Government initiatives and funding also contribute to expanding the market for such complicated diseases. In 2021, IgA nephropathy was rare kidney disease, and the FDA approved the first medication to reduce urine protein. The FDA had approved Tarpeyo (budesonide) delayed-release capsules to treat adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression by lowering proteinuria (increased protein levels in the urine).

Multiple factors, including unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not reflect underlying pathophysiological mechanisms, have impacted therapeutic advancements in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.

Market Segmentation

The Rare Kidney Diseases market is segmented into target indications, type of molecule, and route of administration. Target indication segment includes IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and others. Another segment is a type of molecule, which comprises Small Molecules and biologics. The subsegment biologics include Monoclonal Antibody, Hormone, Recombinant Protein, and Others. The last segment is the route of administration which has Oral, Intravenous, Subcutaneous, and other routes as subsegments.

According to regional analysis, North America will lead the global Rare Kidney Diseases market during the forecast period due to rapid clinical advancement breakthroughs and research for treatments of kidney diseases.

Competitive Landscape

Some major key players in the Rare Kidney Diseases Market:

  • GlaxoSmithKline,
  • Recordati Rare Diseases,
  • Amicus Therapeutics,
  • Calliditas Therapeutics,
  • Alexion Pharmaceuticals (A subsidiary of AstraZeneca),
  • Travere Therapeutics,
  • Aurinia Pharmaceutical,
  • Advicenne,
  • Protalix Biotherapeutics,
  • AstraZeneca,
  • Chinook Therapeutics,
  • Reata Pharmaceuticals,
  • Roche,
  • Novartis Pharmaceuticals,
  • Merk & co.,
  • Apellis Pharmaceuticals,
  • Omeros Corporation,
  • Lonza,
  • Other Prominent Players.

Rare Kidney Diseases Market Report Scope

Report Attribute

Specifications

Market size value in 2022

USD 2528.9 Million

Revenue forecast in 2031

USD 5738.7 Million

Growth rate CAGR

CAGR of 9.7 % from 2023 to 2031

Quantitative units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments covered

Target Indication, Type of Molecule, Route of administration

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Rare Kidney Diseases Market Snapshot

Chapter 4. Global Rare Kidney Diseases Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Target Indication Estimates & Trend Analysis

5.1. by Target Indication & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Target Indication:

5.2.1. IgA Nephropathy

5.2.2. Lupus Nephritis

5.2.3. Focal Segmental Glomerular Sclerosis

5.2.4. Membranous Nephropathy

5.2.5. C3 Glomerulopathy

5.2.6. Cystinosis

5.2.7. Dense Deposit Disease

5.2.8. Distal Renal Tubular Acidosis

5.2.9. Fabry Disease

5.2.10. Refractory Gout

5.2.11. Atypical Hemolytic Uremic Syndrome

5.2.12. Others

Chapter 6. Market Segmentation 2: by Type of Molecule Estimates & Trend Analysis

6.1. by Type Of Molecule & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Type of Molecule:

6.2.1. Small Molecules

6.2.2. Biologics

6.2.2.1. Monoclonal Antibody

6.2.2.2. Hormone

6.2.2.3. Recombinant Protein

6.2.2.4. Others

Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis

7.1. by Route Of Administration & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Route Of Administration:

7.2.1. Oral

7.2.2. Intravenous

7.2.3. Subcutaneous

7.2.4. Others

Chapter 8. Rare Kidney Diseases Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2022-2030

8.1.2. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Type Of Molecule, 2022-2030

8.1.3. North America Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2022-2030

8.1.4. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.2.2. Europe Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.2.3. Europe Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.2.4. Europe Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.3.2. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.3.3. Asia-Pacific Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2022-2030

8.3.4. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.4.2. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.4.3. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.4.4. Latin America Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2022-2030

8.5.2. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2022-2030

8.5.3. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2022-2030

8.5.4. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. GlaxoSmithKline

9.2.2. Recordati Rare Diseases

9.2.3. Amicus Therapeutics

9.2.4. Calliditas Therapeutics

9.2.5. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)

9.2.6. Travere Therapeutics

9.2.7. Aurinia Pharmaceutical

9.2.8. Advicenne

9.2.9. Protalix Biotherapeutics

9.2.10. AstraZeneca

9.2.11. Chinook Therapeutics

9.2.12. Reata Pharmaceuticals

9.2.13. Roche

9.2.14. Novartis Pharmaceuticals

9.2.15. Merk & co

9.2.16. Apellis Pharmaceuticals

9.2.17. Omeros Corporation

9.2.18. Other Prominent Players

Market Segmentation

Global Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)

  • IgA Nephropathy
  • Lupus Nephritis

  • Focal Segmental Glomerular Sclerosis

  • Membranous Nephropathy

  • C3 Glomerulopathy

  • Cystinosis

  • Dense Deposit Disease

  • Distal Renal Tubular Acidosis

  • Fabry Disease

  • Refractory Gout

  • Atypical Hemolytic Uremic Syndrome

  • Others

Rare Kidney Diseases Market

Global Rare Kidney Diseases Market, by Type Of Molecule, 2022-2030 (Value US$ Mn)

  • Small Molecules
  • Biologics
    • Monoclonal Antibody
    • Hormone
    • Recombinant Protein
    • Others

 Global Rare Kidney Diseases Market, by Route Of Administration, 2022-2030 (Value US$ Mn)

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

 Global Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

 Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

 Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

 Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

Who are the Key Players in the Rare Kidney Diseases Market?

The Rare Kidney Diseases Market is expected to grow at a 9.7% CAGR during the forecast period for 2023-2031.

The Rare Kidney Diseases Market Size is valued at 2528.9 Million in 2022 and is predicted to reach 5738.7 Million by the year 2031 at a 9.7% CAGR duri

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach